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Abstract: Anti-inﬂ  ammatory properties may contribute to the pharmacological effects of 
angiotensin II receptor blockers (ARBs), a leading therapeutic class in the management of hyper-
tension and related cardiovascular and renal diseases. That possibility, supported by consistent 
evidence from in-vitro and animal studies showing pro-inﬂ  ammatory properties of angiotensin 
II, has been evaluated clinically by measuring the effect of ARBs on C-reactive protein and 
other circulating indices of inﬂ  ammation (e-selectin, adhesion molecules, interleukin-6, tissue 
necrosis factor-alpha, monocyte chemoattractant protein-1) of potential clinical relevance, a 
body of evidence that this paper aims to review.
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Introduction
The renin–angiotensin system (RAS; Figure 1) is a multi-step peptidergic system by 
which circulating angiotensinogen, a liver-derived α-glycoprotein derived from liver 
and other sources such as the kidney, adipose tissue and the heart,1 is cleaved by renin, 
the rate limiting step in the biological cascade, to form the decapeptide angiotensin 
(Ang) I. In turn, AngI is transformed by angiotensin-converting enzyme (ACE), a 
membrane-bound metalloproteinase expressed in high concentrations on the surface 
of pulmonary endothelial cells,1 into the octapeptide AngII, the ﬁ  nal effector of the 
RAS. The endocrine RAS, as above summarized, works in concert with local RASs, 
ie, self-contained, functionally autonomous AngII-generating systems in the heart, the 
nervous system, reproductive organs, and in interaction with other biological systems, 
eg, endothelins or nitric oxide.2
Most of the cardiovascular effects of AngII are mediated by G coupled type 1 
receptors (AT1Rs) expressed in the vascular wall and organs such as liver, adrenals, 
brain, lung, kidney and the heart, that coexist with type 2 receptors mediating vasodi-
latation, inhibition of cell growth/proliferation and proapoptosis.3 (Pro)renin receptors, 
which accelerate renin catalytic properties, activate circulating prorenin and stimulate 
AngII-independent intracellular signaling pathways, have recently been identiﬁ  ed4 
whose more thorough understanding will likely unveil additional pathophysiologic 
facets of the RAS as a whole (Figure 2).
Each step of the biological cascade leading to AngII, the biological effector of the 
system, can be pharmacologically inhibited by renin inhibitors such as aliskiren, ACE 
inhibitors (ACEIs) and All AT1R blockers (ARBs) (Figure 2), these latter triggering a com-
pensatory renin rise due to the disruption of the feedback inhibition of renin production.1–4 
The increase in renin activity stimulates the conversion of Ang I and Ang II, which may limit 
the efﬁ  cacy of RAS inhibition3 and the increased renin can also activate the prorenin/renin Vascular Health and Risk Management 2009:5 234
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receptor causing renal and cardiovascular damages independent 
of Ang II4 (Figure 2). ARBs constitute a heterogeneous phar-
macological class (Table 1) sharing AT1R antagonism5,6 as a 
common feature whose clinical proﬁ  le has been clariﬁ  ed by 
several published randomized clinical trials7–29 (Table 2) in 
hypertension, cardio-, cerebrovascular disease, diabetes, and 
others either completed30 or on their way to completion31,32 will 
further expand our knowledge on this topic.
Although primarily ascribable to AT1R antagonism of 
the vascular, neurohormonal and renal effects of blood-borne 
and locally produced AngII,1,2 the therapeutic effect of ARBs 
may be compounded by “pleiotropic” mechanisms related 
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Figure 1 The renin–angiotensin system and cascade of bioactive angiotensins.
Abbreviations: ACE2, ACE-related carboxypeptidase; AMP-A, aminopeptidase A; AMP-B, aminopeptidase B; AMP-N, aminopeptidase N; N-EP, neutral endopeptidase; 
P-EP, prolylen-dopeptidase.
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Figure 2 Schematic representation of the classical renin–angiotensin system (RAS) and of the emerging concept integrating the (pro)renin receptor and the blocking of the 
system at different steps by pharmacological compounds.
Abbreviations: Ri, renin inhibitor;   ACEi, angiotensin-converting enzyme inhibitor;   ARB, angiotensin receptor blocker;  (P)RRB, (pro)renin receptor blocker.4Vascular Health and Risk Management 2009:5 235
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to modulation of the multiform effects of AngII on vascular 
cells (Figure 3) by which the peptide may accelerate the 
onset and progression of atherosclerotic vascular disease.33 
Growing evidence, in fact, demonstrates the cytokine-like 
potential of locally-synthesized AngII to act in a paracrine, 
autocrine, and possibly intracrine manner to promote vascular 
inﬂ  ammation, a main component of the atherogenic process 
(see below). That interesting possibility, generated by a con-
sistent series of in-vitro and animal studies, has stimulated 
a number of clinical studies focusing on the effect of ARBs 
on circulating inﬂ  ammatory indices34–78 that this paper will 
discuss.
AngII and vascular inﬂ  ammation
The classical view of atherosclerosis as a lesion composed 
by lipid deposits has now been changed to that of a chronic 
inﬂ  ammatory disorder triggered and maintained by the produc-
tion of inﬂ  ammatory mediators and immune cells involved in 
the initiation, progression, and rupture of the plaque.79 AngII 
may promote and amplify that process through the congeries 
of mechanisms summarized in Figure 3. In fact, All facilitates 
adhesion of monocytes and neutrophils to endothelial cells 
through AT1R-stimulated upregulation of P- and E-selectin 
expression, thus capturing free-ﬂ  owing leukocytes from 
the blood and allowing endothelial rolling. The peptide 
also stimulates the expression of intercellular (ICAM-1) 
and vascular (VCAM-1) cellular adhesion molecules by 
which leukocytes accumulate at the sites of inﬂ  amma-
tion and inﬁ  ltrate the endothelial layer by production of 
chemokines such as monocyte chemoattractant protein-1 
(MCP-1) in endothelial and vascular smooth muscle cells, 
monocytes/macrophages, and cardiac myocytes. AngII 
also increases the expression of cytokines such as inter-
leukin-6 (IL-6) that activates macrophages and adhesion 
molecule expression and increases local angiotensinogen 
generation and thereby local AngII formation in the vascu-
lar wall, further amplifying vascular inﬂ  ammation. AngII, 
by stimulating platelet binding to endothelial cells and/or 
leukocytes, contributes to thrombin release, the main effec-
tor of platelets, that augments the expression of P-selectin, 
E-selectin, VCAM-1, and ICAM-1.79,80 It should, however, 
be clear that the vascular effects of AngII are complex 
Table 1 Main pharmacokinetic characteristics of the available ARBs
Drug Tmax(h) Dose 
range (mg)
Bioavailability 
(%)
Half-life(h) Vd (L) Elimination 
(feces/urine)
Antagonism
Losartan* 1 (3–4) 50–100 33 2 (6–9) 34 (12) 60/35 Competitive
Valsartan 2 80–160 23 6 17 83/13 Competitive
Irbesartan 1–2 150–300 60–80 11–15 53–93 80/20 Insurmountable
Candesartan 3–5 8–32 42 9–12 9 67/33 Insurmountable
Eprosartan 2–6 400–800 13 5–7 13 90/10 Insurmountable
Telmisartan 1 20–80 43 24 500 98% fecal Insurmountable
Olmesartan 1.4–2.8 20–40 26 13 17 35%–49% urine Insurmountable
Abbreviations: ARBs, angiotensin II receptor blockers;   Tmax, time to reach peak serum concentration;   Vd, distribution volume.
Note: *Values in parentheses refer to EXP3174, the active metabolite of losartan.
Table 2 Acronyms of completed and ongoing randomized controlled clinical trials with ARBs
Drug HT Stroke Diabetes/renal CHF MI AF
Candesartan SCOPE15 ACCESS16 ALPINE19 
DIRECT27
CHARM17
Eprosartan MOSES22
Irbesartan IDNT8, IRMAII10 I-PRESERVE28 ACTIVE31
Losartan LIFE12 RENAAL9 ELITE7, HEAAL32 OPTIMAL14
Olmesartan ROADMAP29
Telmisartan ONTARGET24 
TRANSCEND26
PROFESS25 DETAIL21
Valsartan VALUE20 
JIKEI23
MARVAL13 
NAVIGATOR
VALHEFT11 VALIANT18 GISSI-AF30
Abbreviations: AF, atrial ﬁ  brillation;   ARBs, angiotensin II receptor blockers; CHF, congestive heart failure; HT, hypertension; MI, myocardial infarction.Vascular Health and Risk Management 2009:5 236
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and multiform (Figure 3) and involve several intracellular 
pathways leading to inﬂ  ammation and proliferation reviewed 
in detail elsewhere.33,79
Ang II directly act on NAD(P)H oxidase, an enzyme 
present in vascular wall cells consisting of membrane and 
cytoplasmic subunits and a small GTP-binding protein Rac.81 
NAD(P)H oxidase generates reactive oxygen species (ROS) 
that activate nuclear factor kappa B (NFkB), a transcription 
factor binding speciﬁ  c sequences in the promoter regions of 
target genes thus inducing transcription of proinﬂ  ammatory 
cytokines, chemokines, mediators of inﬂ  ammation, immune 
receptors, and adhesion molecules.82 The effect of AngII 
on NFkB has been documented in endothelial and vascular 
smooth muscle, glomerular, tubular, and mononuclear cells 
and its overactivation in tissue of ANGII stimulated animals 
related to AT1R activation.81 ROS excess also impairs endo-
thelial function by decreasing NO bioavailability by both 
constitutive (eNOS) and inducible (iNOS) NO synthases, 
accelerates atherogenesis83 and attenuates BP raise in 
response to AngII infusion,84,85 a piece of evidence sugges-
tive of a role of inﬂ  ammatory components in the genesis of 
essential hypertension.
The effect of ARBs on circulating 
inﬂ  ammatory indices
ARBs and C-reactive protein
C-reactive protein (CRP) is a protein synthesized by hepa-
tocytes under the inﬂ  uence of IL-6 within 24–72 hrs after 
infectious and noninfectious disorders, including myocardial 
infarction and other acute coronary syndromes. Detection of 
both CRP mRNA and protein in vascular smooth muscle cells 
and macrophages within atherosclerotic plaques suggests its de 
novo synthesis in the vessel wall in which CRP may activate 
the complement system and/or interact with macrophages and 
other resident vascular cells.86 Due to its long-term stability 
during storage, long half-life, lack of diurnal variation as well 
as lack of age and sex dependence, circulating CRP represents 
a reliable long-term index of subclinical inﬂ  ammation provided 
of predictive power for cardiovascular events in patients with 
both established coronary artery disease and in primary pre-
vention independent of concomitant factors such as smoking 
status, diabetes, blood pressure, use of hormone-replacement 
therapy and low-density lipoprotein (LDL) cholesterol.87
Because of those favorable characteristics for risk strati-
ﬁ  cation, several studies listed in Table 3 have addressed the 
effect of ARBs on circulating CRP levels in hypertensive and 
diabetic patients. The Val-MARC (Valsartan-Managing blood 
pressure Aggressively and evaluating Reductions in hsCRP) 
study is probably the more important trial addressing the issue 
of whether BP reduction per se lowers CRP levels, or whether 
selective AT1R antagonism through valsartan may have inde-
pendent effects to reduce CRP levels.69 The study included 
1668 patients with stage 2 hypertension randomly allocated to 
either valsartan alone (160–320  mg/day, n = 836) or valsartan/
hydrochlorothiazide (HCTZ, 160–320 mg/12.5 mg/day, n = 832) 
for a period of six weeks. At the end of treatment, valsartan 
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Figure 3 Effects of angiotensin II on vascular cellular biology.
Abbreviations: LDL, low-density lipoprotein; MMP, matrix metallo proteinases; PAI, plasminogen activator inhibitor;   VSMC, vascular smooth muscle cells.Vascular Health and Risk Management 2009:5 237
Angiotensin II type 1 receptor blockers and inﬂ  ammatory indices in man
alone slightly but signiﬁ  cantly reduced high sensitivity (hs)CRP 
levels, an effect maintained over an extended follow-up period 
albeit with a low level of association with achieved BP. As 
CRP levels were unchanged in the combined valsartan/HCTZ 
therapy group, the data were taken as suggestive of a negative 
interaction of thiazide diuretics with the anti-inﬂ  ammatory 
effects of ARBs conclusion. That conclusion contrasts, 
though, with the results of the VAST (Valsartan/HCTZ versus 
Amlodipine in STage II hypertensive patients) trial whose pri-
mary objective was to determine whether valsartan 160 mg plus 
HCTZ 25 mg OD would be more effective than monotherapy 
with amlodipine 10 mg OD.61 Modulation by valsartan of 
CRP levels was conﬁ  rmed in other, small-sized studies in 
patients with hypertension,55 congestive heart failure56 as well 
as normal subjects45 although other reports did not conﬁ  rm 
those data.58,73,77 For example, Rajagopalan and colleagues73 
found no signiﬁ  cant change in hs-CRP in 104 hypertensive 
patients randomized to 12 weeks valsartan (160 mg daily) as 
compared with signiﬁ  cant reductions in those on combined 
statin treatment. Galle and colleagues in the VIVALDI trial 
(inVestigate the efﬁ  cacy of telmIsartan versus VALsartan in 
hypertensive type 2 DIabetic patients with overt nephropa-
thy)77 found no inﬂ  uence of valsartan (160 mg) as well as 
telmisartan (80 mg) on inﬂ  ammatory parameters in 255 hyper-
tensive patients with diabetic nephropathy and the study was 
unable to show any effect beyond that due to blood pressure 
Table 3 Percent changes in high sensitivity (hs) C-reactive protein (CRP) during ARB treatment
Author Type of ARB Dose and duration 
of treatment
Clinical condition 
(n. patients)
Hs-CRP baseline 
(mg/L)
% Change
Wassmann42 C 16 mg × 6 wk HC (17) 7.6 ± 2.7 −24%ns vs P
Dohi46 C 8 mg × 3 mo HT (67) 0.7 ± 0.4 −14%* vs B
Koh47 C 16 mg × 3 mo HT (45) 1.7 (0.11–2.6) NS vs B
Rosei60 C 8–16 mg × 3 mo HT (61) 3.1 ± 2.75 +5%ns vs B
Schram63 C 8 mg × 6–12 mo HT + D (24) 1.97 (1.14–3.65) NS vs B
White75 C 4–32 mg × 6 mo CHF (41) 7 mg/L −26%* vs P
Schieffer54 I 300 mg × 3 mo CAD/HT (21) NR −2.5 mg/L* vs B
Biasucci57 I 300 mg × 1 mo CAD (13) 3.1 (0.7–17.7) −61%* vs P
Andersen34 L 50–100 mg × 2 mo Type 1D (16) 1.0 (0.5–1.82) +16%ns vs P
Prasad38 L 25–50 mg × 2 mo CAD (31) 4.5 ± 1.1 +10%ns vs B
Koh52 L 100 mg × 2 mo HT/HC (47) 0.85 (0.3–1.3) +6%ns vs B
Fliser50 O 20 mg × 3 mo HT/MS (100) 3.56 ± 3.17 −15%* vs B
Miura59 T 40 mg × 3 mo Type 2D (18) 1.54 ± 1.55 −29%* vs B
Koulouris62 T 40 mg × 3 mo Type2D (37) 1.38 ± 1.0 −38%* vs P
Link65 T 40 mg × 3 mo CAD/HT (21) 2.5 ± 0.6 −44%* vs B
Nagel66 T 40 mg × 3 mo HT/MS (20) 5.3 ± 3.77 +8%ns vs B
Yano74 T 40 mg × 3 mo HT/MS (30) 0.77 −22%* vs B
Galle77 T 40–80 mg × 1 yr Type2D + HT (255) 2.1 (0.28–15.8) −3%ns vs B
Nakayama78 T 40 mg/2 mo HT/DIAB (20) 0.76 ± 0.6 +90% vs B
Dandona45 V 160 mg × 1 wk NS (8) 1.27 ± 1.54 −23%* vs B
Yasunari55 V 80 mg × 8 mo HT (52) NR −29%* vs B
Anand56 V 160 mg × 1 yr CHF (106) 3.23 −9.3%* vs B
Manabe58 V 40–80 × 1 mo HT (29) 1.5 ± 1.1 −13%ns vs B
Ruilope61 V 160 mg × 6 mo HT (720) NR −13%* vs B
Ridker69 V 80–160 mg × 6 wk HT (836) 2.11 −8.9%* vs B
Rajagopalan73 V 160 mg × 4 mo HT (107) 3 −5.3%ns vs B
Galle77 V 80–160 mg × 1 yr DIAB + HT (255) 1.88 (0.28–12.59) −3%ns vs B
Abbreviations: C, candesartan; I, irbesartan; L, losartan; O, olmesartan; T, telmisartan;   V, valsartan; CHF, congestive heart failure; HC, hypercholesterolemia; HT, hypertension; 
CAD, coronary artery disease; T2D, type 2 diabetes; T1D, type 1 diabetes; NS, normal subjects; MS, metabolic syndrome; B, baseline; P, concurrent placebo; ns, not signiﬁ  cant.
Note: *denotes statistical signiﬁ  cance (p  0.05 or less) of changes from either baseline or concurrent placebo.Vascular Health and Risk Management 2009:5 238
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control. Nonsigniﬁ  cant changes in hsCRP were reported with 
candesartan42,47,60,63 including the CENTRO (CandEsartaN on 
aTherosclerotic Risk factors) trial, a multicenter, randomized, 
double blind comparison of candesartan and enalapril, an 
ACEI, in hypertensive, diabetic patients showing no effect of 
the ARB (but also enalapril) on hsCRP.60 Similar discrepancies 
also characterized the effect of telmisartan59,62,65,66,74,78 including 
the already commented VIVALDI trial.77 Positive results were 
reported for irbesartan in two studies in coronary heart disease 
patients,54,57 but their small sample size preludes generaliza-
tion. Olmesartan was tested in a well designed and carefully 
conducted prospective, placebo-controlled, double-blind multi-
center study by Fliser and colleagues50 who measured hs-CRP 
levels and other inﬂ  ammatory markers in 199 patients with 
essential hypertension and obesity-related microinﬂ  ammation. 
After 12 weeks of therapy, with additional HTCZ if needed, 
olmesartan decreased hs-CRP (−21.1%; P  0.02), TNF-α 
(−13.6%; P  0.01), IL-6 (−18.0%; P  0.01) and MCP-1 
(−6.5%; P  0.01). Albeit gathered in a well designed and 
carefully conducted study, those results need conﬁ  rmation in 
additional trials, however. A greater anti-inﬂ  ammatory effect 
of olmesartan as compared with telmisartan was recently 
claimed by Nakayama and colleagues,78 but the conclusion 
is ﬂ  awed by the experimental design lacking adequate wash-
out prior to randomization. Notably, losartan did not affect 
CRP in patients with diabetic nephropathy,34 coronary artery 
disease,38 and hypertension.54 No data are available about the 
effect of eprosartan.
ARBs and circulating adhesion molecules, 
cytokines, and chemokines
A number of clinical studies have assessed the effect of 
ARBs on circulating inﬂ  ammatory markers other than CRP 
such as E-selectin, a member of the selectin family expressed 
on the surface of stimulated endothelial cells, and ICAM-1 
and VCAM-1, two immunoglobulin-like molecules acting 
as endothelial ligands to facilitate endothelial adhesion of 
circulating leukocytes.79 Those biological products circulate 
in blood as a result of enzymatic cleavage or from shedding of 
damaged or activated endothelial cells under the inﬂ  uence of 
proatherogenic stimuli such as hypertension, type 2 diabetes, 
obesity as well as established peripheral and coronary artery 
disease.79,88 While the prognostic power of raised s-eSEL is 
dubious,88 circulating ICAM-1 predicted cardiovascular risk 
independent of traditional risk factors in the 14,916 healthy 
men enrolled in the Physicians’ Health Study (PHS),89 as 
well as in the elderly, apparently healthy subjects of the 
Atherosclerosis Risk in Communities (ARIC) study.90 On the 
other hand, VCAM-1 did not predict future cardiovascular 
risk,90 suggesting important distinctions between the roles 
of different CAMs in atherogenesis. Evidence has also been 
gathered in support of the clinical relevance of inﬂ  ammatory 
cytokines such as circulating IL-6 and TNF-α, and MCP-1, 
a chemokine that orchestrates the migration of leukocytes 
into the intima and within atherosclerotic lesions.79 Increased 
plasma IL-6 levels were reported early after admission for 
acute coronary syndromes and associated with a complicated 
in-hospital course and higher IL-6 levels predicted acute 
coronary syndromes in apparently healthy men.91 Post-MI 
elevations of circulating TNF-α92 and MCP-193 also associ-
ated with an increased risk of recurrent coronary events.89
As summarized in Table 4, losartan did not affect 
circulating adhesion molecules in patients with diabetes 
and/or hypertension and/or coronary artery disease34,38,39,53 
while a signiﬁ  cant decrease was reported only in two, small 
studies in normal subjects.41,51 The effect of the drug on eSEL, 
on the other hand, was consistently negative.34,38,39,41,51 The 
same discrepant behavior was shared by candesartan,35,42,60 
the other ARBs frequently used in studies of this kind, while 
either eprosartan40 or telmisartan65 treatment did not change 
VCAM-1 levels to a statistically signiﬁ  cant extent. No data 
are available for irbesartan or olmesartan.
As shown in Table 4, similar considerations hold for the 
effect of ARBs on MCP-1, TNF-α and IL-6.42,47,75
Conclusions
Despite a quite consistent evidence from basic research 
f  ield, the anti-inf  lammatory effect of ARBs in man, at 
least to the extent derived from their effect on circulating 
inﬂ  ammatory indices, is quite inconsistent, a conclusion that 
applies even to studies apparently adopting the same drug at 
similar dosages, comparable patient selection criteria and 
experimental design. Further limitations derive from the 
small sample sizes that characterize many of the available 
studies, heterogeneity of ARBs as a pharmacological class 
(see Table 1), lack of prospective studies evaluating the 
relationship between anti-inﬂ  ammatory effects of ARBs and 
incident morbid events and the complexity of the effects of 
AngII on vascular biology (Figure 3). Additional difﬁ  culties 
derive from the inherent variability of circulating inﬂ  amma-
tory indices, a pattern emerging quite clearly from Table 3 to 
which genetic factors acting at the individual94 as well as the 
population95 level may contribute. Not unlike ARBs, ACEIs 
showed divergent results,96 sometimes in contrast with the 
effects of the ARBs. Thus, enalapril but not losartan reduced 
inﬂ  ammatory markers in hypertensive and diabetic patients.39 Vascular Health and Risk Management 2009:5 239
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It should also be noted that interference on inﬂ  ammatory 
indices is not speciﬁ  c for RAS inhibitors since other classes 
of cardiovascular drugs such as beta-adrenoceptor blocking 
drugs,97,98 statins99 as well as nonpharmacological interven-
tions such as exercise training, weight loss94 and nutritional 
factors100 may inﬂ  uence CRP levels. Suggestions have also 
been raised about a beneﬁ  cial effect of intensive blood pres-
sure and lipid treatment per se.101 Moreover, the validity of 
circulating inﬂ  ammatory markers as a surrogate end-point 
for an underlying inﬂ  ammatory process is unclear since the 
relationship with their activity at the local level is unknown. 
Importantly, modiﬁ  cations in circulating CRP, even when 
highly consistent such as in the case of statins,99 have dubious 
pathophysiological signiﬁ  cance since decrements in hsCRP 
were associated with either no change,102,103 or improved 
cardiovascular prognosis.104 As a matter of fact, the LDL- and 
CRP-lowering effect of statins99,105 are closely intertwined, 
possibly as an expression of their metabolic effect on the liver. 
For these reasons, no ﬁ  rm conclusions can be drawn about 
their effect at this point and further studies are needed.
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